(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 February 2011 (03.02.2011)

PCT

(10) International Publication Number
WO 2011/014588 A2

(51) International Patent Classification:
A61K 31/195 (2006.01) *A61K 9/00* (2006.01)
A61K 31/185 (2006.01) *A61P 17/02* (2006.01)
A61K 47/06 (2006.01) *A61P 17/00* (2006.01)

(21) International Application Number:
PCT/US2010/043599

(22) International Filing Date:
28 July 2010 (28.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/230,585 31 July 2009 (31.07.2009) US

(71) Applicant *(for all designated States except US)*: **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street, Suite 100, San Diego, California 92121 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **HUTCHINSON, John Howard** [US/US]; 3435 Richmond Street, San Diego, California 92103 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title**: DERMAL FORMULATIONS OF DP_2 RECEPTOR ANTAGONISTS



	Plasma conc. (nM) @ trough
Compd I 10 mg/kg, qd	< 10
Compd II 30 g/kg, b.i.d.	168
Compd I Compd II	<10 (2206)/136 (802)

Figure 1

(57) **Abstract**: Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP_2 receptor antagonist compound formulated for dermal administration

WO 2011/014588 A2